Recombinant envelope glycoprotein domain III of dengue virus inhibit virus infection.
- Author:
Peng LU
1
;
Yan WEI
;
Shou-Chun CAO
;
Jian-Dong LI
;
Qin-Zhi LIU
;
Quan-Fu ZHANG
;
Chuan LI
;
Fang MIAO
;
Shuo ZHANG
;
Xiao-Tong HANG
;
Mi-Fang LIANG
;
De-Xin LI
Author Information
- Publication Type:Journal Article
- MeSH: Animals; Antibodies, Viral; immunology; Cell Line; Cricetinae; Dengue; immunology; prevention & control; virology; Dengue Virus; chemistry; genetics; immunology; physiology; Down-Regulation; Escherichia coli; genetics; metabolism; Humans; Immunization; Mesocricetus; Protein Structure, Tertiary; Rabbits; Recombinant Proteins; chemistry; genetics; immunology; Viral Envelope Proteins; chemistry; genetics; immunology; Virus Replication
- From: Chinese Journal of Experimental and Clinical Virology 2008;22(3):177-179
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo observe the ability of dengue virus recombinant envelope protein domain expressed in E. coli to inhibit virus infection and induce the neutralizing antibody.
METHODSE III protein of Dengue virus serotypes 1-4 were expressed in E. coli BL21(DE3) then purified. Recombinant proteins were tested to inhibit DV2 from infecting BHK-21 cell. Rabbits were immunized with recombinant proteins to produce anti-E III serum. Antibody titers were determined by neutralizing assay.
RESULTSThe recombinant E III proteins of Dengue virus serotypes 1-4 were expressed in E. coli. They effectively protected BHK cells in culture against DV2 infection. All four type anti-E III sera can neutralize DV2 but their efficacies are different.
CONCLUSIONproteins of dengue virus expressed in E. coli can directly inhibit DV2 infection. Neutralizing antibodies were induced by E III proteins. Both E III protein of dengue virus and the neutralizing antibodies they induced are more efficient in inhibiting homologous dengue serotypes infection than heterologous serotypes.
